tnt: treating to new targets
principal researchers
John LaRosa (State University of New York)
data custodian
Viatris Inc (originally Pfizer Inc.)
funding
Pfizer Inc.
key publications
- Design paper: Am J Cardiol 2004; 93: 154-158
- Main results: N Engl J Med 2005; 352: 1425-35
- Short-term abrupt statin discontinuation: Circulation 2004; 110: 2333-5 (302)
- Substantially lowering cholesterol: Diabetes Care 2006; 29: 1220-6 (303)
- High dose atorvastatin: J Am Coll Cardiol 2006; 48: 1793-9 (304)
- Reducing LDL cholesterol: Lancet 2006; 368: 919-28 (305)
- Safety and efficacy: Am J Cardiol 2007; 100(5): 747-52
- Effects on renal function: Clin J Am Soc Nephrol 2007; 2(6): 1131-9
- Effects in those over 65 years old: Ann Intern Med 2007; 147(1): 1-9
- Hospitalizations for heart failure: Circulation 2007; 115: 576-83 (309)
- HDL Cholesterol: N Engl J Med 2007; 357: 1301-10 (310)
- Previous percutaneous coronary intervention: Am J Cardiol 2008; 102: 1312-7 (311)
- Lipids, apolipoproteins, and their ratios: Circulation 2008; 117: 3002-9 (312)
- Effects by gender: Heart 2008; 94(4): 434-9
- Chronic kidney disease: J Am Coll Cardiol 2008; 51: 1448-54 (314)
- Secondary prevention: J Am Coll Cardiol 2008; 51: 1938-43 (315)
- Blood pressure: J Clin Hypertens 2008; 10: 367-76. (316)
- Coronary artery disease, diabetes, and chronic kidney disease: Mayo Clin Proc 2008; 83: 870-9 (317)
- Plasma triglycerides and cardiovascular events: Am J Cardiol 2009; 104: 459-63 (230)
- Whole-genome and candidate gene analysis: Circ Cardiovasc Genet 2009; 2: 173-81 (318)
- Events after first event: Am J Cardiol 2010; 105: 283-7 (319)
- Heart rate at rest: Am J Cardiol 2010; 105: 905-11 (320)
- Genetic association of the CCR5 region: Circ Cardiovasc Genet 2010; 3: 162-8 (235)
- Blood pressure and CV events: Eur Heart J 2010; 31: 2897-908 (321)
- Impact of smoking: Am J Cardiol 2011; 107: 145-50 (238)
- 719Arg variant of KIF6: Circ Cardiovasc Genet 2012; 5: 51-7 (241)
- On treatment lipoprotein components: Eur J Clin Invest 2011; 41: 134-42 (322)
- GFR improvement: Am J Cardiol 2012; 109: 1761-6 (323)
- Inflammatory joint disease: Arthritis Rheum 2012; 64: 2836-46 (240)
- Residual risk in secondary prevention patients: Circulation 2012; 125: 1979-87 (324)
- Patients with ankylosing spondylitis and psoriatic arthritis: J Rheumatol 2012; 39: 1433-40 (325)
- Stable coronary artery disease: Circulation 2013; 127: 2485-93 (242)
- Effect of baseline risk factors for diabetes: J Am Coll Cardiol 2013; 61: 148-52 Erratum in: J Am Coll Cardiol 2014; 64: 1970 (243)
- Effect of change in body weight on incident diabetes mellitus: Am J Cardiol 2014; 113: 1593-8 Erratum in: Am J Cardiol 2015; 115: 1323 (326)
- Treatment-resistant hypertension: Am J Med. 2014; 127: 71-81.e1 (327)
- Treatment resistant hypertension: Eur Heart J 2014; 35(27): 1801-8 (328)
- Lipid and non-lipid biomarkers. PLoS One 2014; 9: e114519 (329)
- Risk of new-onset diabetes: J Am Coll Cardiol 2015; 65: 402-4 (245)
- Oxidized phospholipids on apolipoprotein B-100: J Am Coll Cardiol 2015; 65: 1286-95 (330)
- Low-density lipoprotein cholesterol variability: J Am Coll Cardiol 2015; 65: 1539-48 (331)
- Metabolic syndrome: Diabetes Obes Metab 2015; doi: 10.1111/dom.12581 (332)